Drugs / GC019F
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04595162 | Mar 2021 → Dec 2023 overdue | B-cell acute lymphoblastic leukemia | Peking University Third Hospital | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-01-19 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Regulatory Gracell Biotechnologies Receives IND Approval from China NMPA for GC019F, a FasTCAR-Enabled CAR-T Therapy for the Treatment of Relapsed or Refractory Adult B-ALL gracellbio.com ↗
the National Medical Products Administration (NMPA) in China has approved an investigational new drug (IND) application to study GC019F, a FasTCAR-enabled chimeric antigen receptor (CAR)-T therapy in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia (B-ALL). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-01-19 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Gracell Biotechnologies Receives IND Approval from China NMPA for GC019F, a FasTCAR-Enabled CAR-T Therapy for the Treatment of Relapsed or Refractory Adult B-ALL gracellbio.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC019F | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04595162 ↗ |
| Modality | Cell therapy | “GC019F is the CAR-T cell immunotherapy targeted CD19.” NCT04595162 ↗ |
| Route | Other | “one single infusion of GC019F” NCT04595162 ↗ |
| Target | CD19 | “targeted CD19” NCT04595162 ↗ |